Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Evaluation of the coding genome of diffuse giant B-cell lymphoma. Nat Genet. 2011;43:830–7.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–95.
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective inhibition of HDAC3 targets artificial vulnerabilities and prompts immune surveillance in lymphoma. Most cancers Discov. 2020;10:440–59.
Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6:130–40.
Schroers-Martin JG, Soo J, Brisou G, Scherer F, Kurtz DM, Sworder BJ, et al. Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors. Most cancers Discov 2023;13:1310–23.
Inexperienced MR, Kihira S, Liu CL, Nair RV, Salari R, Gentles AJ, et al. Mutations in early follicular lymphoma progenitors are related to suppressed antigen presentation. Proc Natl Acad Sci. 2015;112:E1116–E1125.
Mondello P, Fama A, Larson MC, Feldman AL, Villasboas JC, Yang ZZ, et al. Lack of intrafollicular reminiscence CD4 + T cells is predictive of early scientific failure in newly recognized follicular lymphoma. Blood Most cancers J. 2021;11:130.
Mondello P, Ansell SM, Nowakowski GS. Immune epigenetic crosstalk between malignant B cells and the tumor microenvironment in B cell lymphoma. Entrance Genet. 2022;13:826594.
He MY, Tong KI, Liu T, Hawkins RW, Shelton V, Zeng Y, et al. GNAS knockout potentiates HDAC3 inhibition via viral mimicry-related interferon responses in lymphoma. Leukemia. 2024. in press
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell remedy in refractory giant B-Cell lymphoma. N. Engl J Med. 2017;377:2531–44.
Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, et al. Glofitamab for relapsed or refractory diffuse giant B-Cell Lymphoma. N Engl J Med. 2022;387:2220–31.
Ennishi D, Takata Ok, Béguelin W, Duns G, Mottok A, Farinha P, et al. Molecular and genetic characterization of MHC deficiency identifies ezh2 as therapeutic goal for enhancing immune recognition. Most cancers Discov. 2019;9:546–63.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl J Med. 2015;372:311–9.
Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, et al. Nivolumab for relapsed/refractory diffuse giant B-cell lymphoma in sufferers ineligible for or having failed autologous transplantation: A single-arm, part II examine. J Clin Oncol. 2019;37:481–9.
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, et al. Improved efficacy of Tafasitamab plus Lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort examine. Clin Most cancers Res. 2022;28:4003–17.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, et al. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based mostly on real-world information in sufferers with relapsed/refractory diffuse giant B-cell lymphoma. Ann Hematol. 2023;102:1773–87.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, et al. Selinexor in sufferers with relapsed or refractory diffuse giant B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, part 2 trial. Lancet Haematol. 2020;7:e511–e522.
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse giant B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, part 2 trial. Lancet Oncol. 2021;22:790–800.
Wilson WH, Wright GW, Huang DW, Hodkinson B, Balasubramanian S, Fan Y, et al. Impact of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Most cancers Cell. 2021;39:1643–53.
Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, et al. Panobinostat acts synergistically with ibrutinib in diffuse giant B cell lymphoma cells with MyD88 L265 mutations. JCI Perception. 2017;2:e90196.
Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, et al. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell dying. Proc Natl Acad Sci. 2018;115:12034–9.
Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, et al. Twin inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic exercise in opposition to B cell lymphoma. Oncotarget. 2017;8:14017–28.
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, et al. Polatuzumab Vedotin in beforehand untreated diffuse giant B-Cell Lymphoma. N. Engl J Med. 2022;386:351–63.
Ysebaert L, Lemonnier F, Brisou G, Casasnovas O, Pica GM, Bachy E, et al. Tazemetostat together with R-CHOP in sufferers with high-risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Part II examine from the Lysa. Blood. 2023;142:297.
